

SARS-2 Variant Declaration

Date: December, 22, 2020

Ref. no:NETIVD1222-AD

We, NanoEntek Inc., duly existing under the laws of Republic of Korea and having its principle place at 12F, ACE High-end Tower, 5, Digital-ro, 26-gil, Guro-gu, Seoul, 08389, Korea, hereby update you on the SARS-2 mutation association. Below table shows the detectability of recently identified mutations of SARS CoV 2 targets using FRENDO COVID-19 Ag through in silico sequence analysis.

	Mutation	FRENDO COVID-19 Ag
<u>NUCLEOCAPSID</u>	G29140T	Detect

*mutation is not associated with sequence regions targeted by NanoEntek's assays

We inform you that FRENDO-COVID-19 Ag does not target in any way the S protein region, therefore, our product can detect UK new variant (B.1.1.7 lineage)



NanoEntek, Inc / C.S. Lee / Director of the NanoEntek Development Department